NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only patients with triple-negative breast cancer (TNBC) will be eligible for the dose expansion phase of the study
Exclusions: Patients with prior treatment of an antibody drug conjugate (ADC) containing an auristatin or maytansinoid payload; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with history of leptomeningeal disease

Comments are closed.

Up ↑